Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

M. Wenzel, L. Nocera, C. Collà Ruvolo, C. Würnschimmel, Z. Tian, SF. Shariat, F. Saad, D. Tilki, M. Graefen, LA. Kluth, A. Briganti, P. Mandel, F. Montorsi, FKH. Chun, PI. Karakiewicz

. 2022 ; 25 (2) : 139-148. [pub] 20210530

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, metaanalýza, přehledy, systematický přehled, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019452

BACKGROUND: The most recent overall survival (OS) and adverse event (AE) data have not been compared for the three guideline-recommended high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treatment alternatives. METHODS: We performed a systematic review and network meta-analysis focusing on OS and AE according to the most recent apalutamide, enzalutamide, and darolutamide reports. We systematically examined and compared apalutamide vs. enzalutamide vs. darolutamide efficacy and toxicity, relative to ADT according to PRISMA. We relied on PubMed search for most recent reports addressing prospective randomized trials with proven predefined OS benefit, relative to ADT: SPARTAN, PROSPER, and ARAMIS. OS represented the primary outcome and AEs represented secondary outcomes. RESULTS: Overall, data originated from 4117 observations made within the three trials that were analyzed. Regarding OS benefit relative to ADT, darolutamide ranked first, followed by enzalutamide and apalutamide, in that order. In the subgroup of PSA-doubling time (PSA-DT) ≤ 6 months patients, enzalutamide ranked first, followed by darolutamide and apalutamide in that order. Conversely, in the subgroup of PSA-DT 6-10 months patients, darolutamide ranked first, followed by apalutamide and enzalutamide, in that order. Regarding grade 3+ AEs, darolutamide was most favorable, followed by enzalutamide and apalutamide, in that order. CONCLUSION: The current network meta-analysis suggests the highest OS efficacy and lowest grade 3+ toxicity for darolutamide. However, in the PSA-DT ≤ 6 months subgroup, the highest efficacy was recorded for enzalutamide. It is noteworthy that study design, study population, and follow-up duration represent some of the potentially critical differences that distinguish between the three studies and remained statistically unaccounted for using the network meta-analysis methodology. Those differences should be strongly considered in the interpretation of the current and any network meta-analyses.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019452
003      
CZ-PrNML
005      
20220804135656.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41391-021-00395-4 $2 doi
035    __
$a (PubMed)34054128
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Wenzel, Mike $u Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany. Mike.Wenzel@kgu.de $u Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada. Mike.Wenzel@kgu.de $1 https://orcid.org/0000000243380889
245    10
$a Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis / $c M. Wenzel, L. Nocera, C. Collà Ruvolo, C. Würnschimmel, Z. Tian, SF. Shariat, F. Saad, D. Tilki, M. Graefen, LA. Kluth, A. Briganti, P. Mandel, F. Montorsi, FKH. Chun, PI. Karakiewicz
520    9_
$a BACKGROUND: The most recent overall survival (OS) and adverse event (AE) data have not been compared for the three guideline-recommended high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treatment alternatives. METHODS: We performed a systematic review and network meta-analysis focusing on OS and AE according to the most recent apalutamide, enzalutamide, and darolutamide reports. We systematically examined and compared apalutamide vs. enzalutamide vs. darolutamide efficacy and toxicity, relative to ADT according to PRISMA. We relied on PubMed search for most recent reports addressing prospective randomized trials with proven predefined OS benefit, relative to ADT: SPARTAN, PROSPER, and ARAMIS. OS represented the primary outcome and AEs represented secondary outcomes. RESULTS: Overall, data originated from 4117 observations made within the three trials that were analyzed. Regarding OS benefit relative to ADT, darolutamide ranked first, followed by enzalutamide and apalutamide, in that order. In the subgroup of PSA-doubling time (PSA-DT) ≤ 6 months patients, enzalutamide ranked first, followed by darolutamide and apalutamide in that order. Conversely, in the subgroup of PSA-DT 6-10 months patients, darolutamide ranked first, followed by apalutamide and enzalutamide, in that order. Regarding grade 3+ AEs, darolutamide was most favorable, followed by enzalutamide and apalutamide, in that order. CONCLUSION: The current network meta-analysis suggests the highest OS efficacy and lowest grade 3+ toxicity for darolutamide. However, in the PSA-DT ≤ 6 months subgroup, the highest efficacy was recorded for enzalutamide. It is noteworthy that study design, study population, and follow-up duration represent some of the potentially critical differences that distinguish between the three studies and remained statistically unaccounted for using the network meta-analysis methodology. Those differences should be strongly considered in the interpretation of the current and any network meta-analyses.
650    _2
$a benzamidy $7 D001549
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a síťová metaanalýza $7 D000071076
650    _2
$a nitrily $7 D009570
650    _2
$a fenylthiohydantoin $7 D010669
650    _2
$a prospektivní studie $7 D011446
650    _2
$a prostatický specifický antigen $7 D017430
650    12
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $x patologie $7 D064129
650    _2
$a pyrazoly $7 D011720
650    _2
$a thiohydantoiny $7 D013867
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a přehledy $7 D016454
655    _2
$a systematický přehled $7 D000078182
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nocera, Luigi $u Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy $1 https://orcid.org/0000000333548139
700    1_
$a Collà Ruvolo, Claudia $u Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada $u Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy $1 https://orcid.org/0000000181107341
700    1_
$a Würnschimmel, Christoph $u Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000178914791
700    1_
$a Tian, Zhe $u Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czechia $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan $1 https://orcid.org/0000000314269273
700    1_
$a Saad, Fred $u Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada
700    1_
$a Tilki, Derya $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany $u Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000170331380
700    1_
$a Graefen, Markus $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Kluth, Luis A $u Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Mandel, Philipp $u Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Montorsi, Francesco $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Chun, Felix K H $u Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Karakiewicz, Pierre I $u Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada
773    0_
$w MED00008064 $t Prostate cancer and prostatic diseases $x 1476-5608 $g Roč. 25, č. 2 (2022), s. 139-148
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34054128 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135649 $b ABA008
999    __
$a ok $b bmc $g 1822875 $s 1170695
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 25 $c 2 $d 139-148 $e 20210530 $i 1476-5608 $m Prostate cancer and prostatic diseases $n Prostate Cancer Prostatic Dis $x MED00008064
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace